ASH 2025 Insights: PNH Risks When Switching Complement Inhibitors скачать в хорошем качестве

ASH 2025 Insights: PNH Risks When Switching Complement Inhibitors

2025 American Society of Hematology Expert Insights: PNH Risks When Switching Complement Inhibitors New data presented at the 2025 American Society of Hematology (ASH) Annual Meeting highlight important safety considerations when switching complement inhibitors in paroxysmal nocturnal hemoglobinuria (PNH). In this discussion, Dr. Gloria Gerber, MD (Johns Hopkins University), shares expert clinical perspective on these risks. This video serves as one installment in a multi-part series of expert conversations and study highlights from the 2025 American Society of Hematology (ASH) Annual Meeting. Subscribe for ongoing conference coverage and perspectives from leaders at the forefront of hematology and cellular therapy. 🎤 Speaker: Gloria Gerber, MD, John Hopkins University 🎤 Interviewer: Bethany Samuelson Bannow, MD, MCR, Deputy Editor, ASH Clinical News The discussion is grounded in findings from an international cohort analysis presented by Morag Griffin, MBChB, examining hemolytic events following switches between complement inhibitor classes. The study highlights a heightened risk of hemolysis—particularly when transitioning from proximal to terminal complement inhibition—and underscores the clinical importance of avoiding treatment gaps or interruptions during therapy changes. Dr. Gerber addresses how these data inform real-world decision-making, including practical considerations when switching between proximal and terminal complement inhibitors, vigilance for hemolytic flares, and how emerging therapies may shape future management strategies for patients with PNH. 📖🔗 Read the full article: “Vigilance Needed to Prevent Hemolytic Events When Switching Complement Inhibitors in PNH” https://ashpublications.org/ashclinic... 📚🔗 Want more? Discover more Hematology insights: https://focus.wiley.com/topic/amps-su... This video is intended for hematologists, oncologists, and clinical researchers interested in PNH, complement-targeted therapies, and novel RNA-based treatments. #ASH2025 #redbloodcells #irondisorders #hematology #PNH #complementinhibitors